Priessner, Martin http://orcid.org/0009-0005-7349-283X
Gaboriau, David C. A. http://orcid.org/0000-0003-4047-6487
Sheridan, Arlo
Lenn, Tchern http://orcid.org/0000-0002-5827-4616
Garzon-Coral, Carlos http://orcid.org/0000-0002-7589-338X
Dunn, Alexander R. http://orcid.org/0000-0001-6096-4600
Chubb, Jonathan R.
Tousley, Aidan M. http://orcid.org/0000-0002-3286-0238
Majzner, Robbie G. http://orcid.org/0000-0001-6969-8011
Manor, Uri http://orcid.org/0000-0002-9802-1955
Vilar, Ramon
Laine, Romain F. http://orcid.org/0000-0002-2151-4487
Article History
Received: 29 November 2021
Accepted: 17 November 2023
First Online: 18 January 2024
Competing interests
: R.G.M. and A.M.T. hold several patents in the field of CAR-T cell immunotherapy. R.G.M. is a co-founder of and holds equity in Syncopation Life Sciences/Cargo Therapeutics and Link Cell Therapies. R.G.M. is a consultant for NKarta, Arovella Pharmaceuticals, Innervate Radiopharmaceuticals, GammaDelta Therapeutics, Aptorum Group, Zai Labs, ImmunAI, Gadeta, FATE Therapeutics (DSMB) and Waypoint Bio. A.M.T. is a consultant for and holds equity in Syncopation Life Sciences and Link Cell Therapies. The remaining authors declare no competing interests.